Evaluation of lipoprotein(a) as a prothrombotic factor: Progress from bench to bedside

Current Opinion in Lipidology

Volumn 14, Issue 4, 2003, Pages 361-366

  Marcovina, Santica M ^a   Koschinsky, Marlys L ^b  

^a UNIVERSITY OF WASHINGTON   (United States)

^b QUEEN S UNIVERSITY   (Canada)

Author keywords

Fibrinolysis; Ischemic stroke; Lipoprotein(a); Plasminogen activation; Venous thrombosis

Indexed keywords

APOLIPOPROTEIN A; FIBRIN; LIPOPROTEIN A; PLASMINOGEN; TISSUE PLASMINOGEN ACTIVATOR;

ADULT; ANIMAL MODEL; ATHEROSCLEROSIS; BINDING SITE; CARDIOVASCULAR DISEASE; CEREBROVASCULAR DISEASE; CHILD; FIBRINOLYSIS; HUMAN; MAJOR CLINICAL STUDY; NONHUMAN; PLASMINOGEN ACTIVATION; PRIORITY JOURNAL; REVIEW; RISK FACTOR; STROKE; THROMBOEMBOLISM; THROMBOGENESIS;

ANIMALS; BLOOD COAGULATION FACTORS; CLINICAL TRIALS; FIBRINOLYSIS; HUMANS; LIPOPROTEIN(A); PLASMINOGEN; THROMBOSIS; TISSUE PLASMINOGEN ACTIVATOR;

ANIMALIA;

EID: 0041624201     PISSN: 09579672     EISSN: None     Source Type: Journal    
DOI: 10.1097/00041433-200308000-00004     Document Type: Review

References (47)

1. Berg K. A new serum type system in man: the Lp system. Acta Pathol Microbiol Scand 1963; 59:362-382.
2. Marcovina SM, Koschinsky ML. A critical evaluation of the role of Lp(a) in cardiovascular disease: can Lp(a) be useful in risk assessment? Semin Vasc Med 2002; 2:335-344. A recent and comprehensive review covering the role of Lp(a) as a risk factor primarily for coronary heart disease; potential mechanisms of the atherogenicity are also addressed.
3. McLean JW, Tomlinson JE, Kuang W-J, et al. cDNA sequence of human apolipoprotein(a) is homologous to plasminogen. Nature 1987; 330:132-137.
4. Gabel BR, Koschinsky ML. Analysis of the proteolytic activity of a recombinant form of apolipoprotein(a). Biochemistry 1995; 34:15777-15784.
5. van der Hoek YY, Wittekoek ME, Beisiegel U, et al. The apolipoprotein(a) kringle IV repeats which differ from the major repeat kringle are present in variably-sized isoforms. Hum Mol Genet 1993; 2:361-366.
6. Lackner C, Cohen JC, Hobbs HH. Molecular definition of the extreme size polymorphism in apolipoprotein(a). Hum Mol Genet 1993; 2:933-940.
7. Marcovina S, Hobbs HH, Albers J. Relation between number of apolipoprotein(a) kringle 4 repeats and mobility of isoforms in agarose gel: basis for a standardized isoform nomenclature. Clin Chem 1996; 42:436-439.
8. Gabel BR, Koschinsky ML. Sequences within apolipoprotein(a) kringle IV types 6-8 bind directly to low-density lipoprotein and mediate noncovalent association of apolipoprotein(a) with apolipoprotein B-100. Biochemistry 1998; 37:7892-7898.
9. LoGrasso PV, Cornell-Kennon S, Boettcher BR. Cloning, expression, and characterization of human apolipoprotein(a) kringle IV37. J Biol Chem 1994; 269:21820-21827.
10. Rahman MN, Becker L, Petrounevitch V, et al. Comparative analyses of the lysine binding site properties of apolipoprotein(a) kringle IV types 7 and 10. Biochemistry 2002; 41:1149-1155.
11. Gabel BR, May LF, Marcovina SM, Koschinsky ML. Lipoprotein(a) assembly: quantitative assessment of the role of apo(a) kringle IV types 2-10 in particle formation. Arterioscler Thromb Vasc Biol 1996; 16:1559-1567.
12. Ernst A, Helmhold M, Brunner C, et al. Identification of two functionally distinct lysine-binding sites in kringle 37 and in kringles 32-36 of human apolipoprotein(a). J Biol Chem 1995; 270:6227-6234.
13. Loscalzo J, Weinfeld M, Fless GM, Scanu AM. Lipoprotein(a), fibrin binding, and plasminogen activation. Arteriosclerosis 1990; 10:240-245.
14. Edelberg JM, Gonzalez-Gronow M, Pizzo SV. Lipoprotein(a) inhibition of plasminogen activation by tissue-type plasminogen activator. Thromb Res 1990; 57:155-162.
15. Sangrar W, Bajzar L, Nesheim ME, Koschinsky ML. Antifibrinolytic effect of recombinant apolipoprotein(a) in vitro is primarily due to attenuation of tPA-mediated Glu-plasminogen activation. Biochemistry 1995; 34:5151-5157.
16. Anglés-Cano E, de la Peña Díaz A, Loyau S. Inhibition of fibrinolysis by lipoprotein(a). Ann N Y Acad Sci 2001; 936:261-275.
17. Kang C, Dominguez M, Loyau S, et al. Lp(a) particles mold fibrin-binding properties of apo(a) in size-dependent manner: a study with different-length recombinant apo(a), native Lp(a), and monoclonal antibody. Arterioscler Thromb Vasc Biol 2002; 22:1232-1238. Identifies a mechanism by which smaller-sized Lp(a) isoforms might pose a greater risk for atherothrombotic disease; interestingly, enhanced affinity for fibrin is a property of Lp(a) species containing smaller apo(a) isoforms whereas differently sized apo(a) species not associated with LDL do not differ in their affinity for fibrin.
18. Sangrar W, Gabel BR, Boffa MB, et al. The solution phase interaction between apolipoprotein(a) and plasminogen inhibits the binding of plasminogen to a plasmin-modified fibrinogen surface. Biochemistry 1997; 36:10353-10363.
19. Hancock MA, Boffa MB, Marcovina SM, et al. Inhibition of plasminogen activation by lipoprotein(a): critical domains in apelipoprotein(a) and mechanism of inhibition on fibrin and degraded fibrin surfaces. J Biol Chem 2003; 287(26):23260-23269. Reports the results of an extensive series of kinetic experiments utilizing a fluorescent derivative of recombinant plasminogen that does not develop catalytic activity; as such, the analysis is not complicated by the feedback mechanisms inherent in the fibrinolytic cascade. The data are consistent with an equilibrium template model in which apo(a) inhibits plasminogen activation not by displacing plasminogen from binding sites on fibrin but rather by binding to the catalytic complex of plasminogen, tPA, and fibrin. The resultant complex containing apo(a) displays a reduced turnover number.
20. Falco C, Estelles A, Dalmau J, et al. Influence of lipoprotein(a) levels and isoforms on fibrinolytic activity: study in families with high lipoprotein(a) levels. Thromb Haemost 1998; 79:818-823.
21. Rand ML, Sangrar W, Hancock MA, et al. Apolipoprotein(a) enhances platelet responses to the thrombin receptor-activating peptide SFLLRN. Arterioscler Thromb Vasc Biol 1998; 18:1393-1399.
22. Caplice NM, Panetta C, Peterson TE, et al. Lipoprotein(a) binds and inactivates tissue factor pathway inhibitor: a novel link between lipoproteins and thrombosis. Blood 2001; 98:2980-2987.
23. Lawn RM, Boonmark NW, Schwartz K, et al. The recurring evolution of lipoprotein(a): insights from cloning of hedgehog apolipoprotein(a). J Biol Chem 1995; 270:24004-24009.
24. Williams JK, Bellinger DA, Nichols TC, et al. Occlusive arterial thrombosis in cynomolgus monkeys with varying plasma concentrations of lipoprotein(a). Arterioscler Thromb 1993; 13:548-554.
25. Palabrica TM, Liu AC, Aronovitz MJ, et al. Antifibrinolytic activity of apolipoprotein(a) in vivo: human apolipoprotein(a) transgenic mice are resistant to tissue plasminogen activator-mediated thrombolysis. Nat Med 1995; 1:256-259.
26. Biemond BJ, Friederich PW, Koschinsky ML, et al. Apolipoprotein(a) attenuates endogenous fibrinolysis in the rabbit jugular vein thrombosis model in rive. Circulation 1997; 96:1612-1615.
27. Fan J, Challah M, Shimoyamada H, Watanabe T. Transgenic rabbits expressing human apolipoprotein(a) as a useful model for the study of lipoprotein(a). Ann N Y Acad Sci 2000; 902:347-351.
28. Fan J, Shimoyamada H, Sun H, et al. Transgenic rabbits expressing human apolipoprotein(a) develop more extensive atherosclerotic lesions in response to a cholesterol-rich diet. Arterioscler Thromb Vasc Biol 2001; 21:88-94.
29. Sun H, Unoki H, Wang X, et al. Lipoprotein(a) enhances advanced atherosclerosis and vascular calcification in WHHL transgenic rabbits expressing human apolipoprotein(a). J Biol Chem 2002; 277:47486-47492. Describes a transgenic rabbit model in which human apo(a) is expressed in the Watanabe Heritable Hyperlipidemic rabbit which lacks the LDL receptor. Expression of apo(a) (which becomes incorporated into chimeric Lp(a) particles containing rabbit LDL) dramatically enhances the extent of spontaneous atherosclerotic lesion formation. The lesions resemble complex lesions observed in advanced human disease.
30. Liu AC, Lawn RM. Lipoprotein(a) and atherogenesis. Trends Cardiovasc Med 1994; 4:40-44.
31. Roller RE, Trinker M, Schnedl WJ, et al. Lack of association between elevated serum Lp(a) and local thrombus lysability in patients with peripheral arterial occlusive disease. Blood Coagul Fibrinolysis 1999; 10:449-450.
32. Çelik S, Baykan M, Örem C, et al. Serum lipoprotein(a) and its relation to left ventricular thrombus in patients with acute myocardial infarction. Jpn Heart J 2001; 42:5-14.
33. Lip GY. Lipoprotein(a) and thrombogenesis in left ventricular dysfunction. Eur Heart J 2001; 22:181-182.
34. Gatica A, Panes O, Tagle R, et al. High plasma levels of lipoprotein(a) in uremic patients are related to markers of inflammation, and to activated, not impaired, fibrinolysis. Thromb Haemost 2002; 88:688-689.
35. Ignatescu M, Kostner K, Zorn G, et al. Plasma Lp(a) levels are increased in patients with chronic thromboembolic pulmonary hypertension. Thromb Haemost 1998; 80:231-232.
36. Igarashi Y, Kasai H, Yamashita F, et al. Lipoprotein(a), left atrial appendage function and thromboembolic risk in patients with chronic nonvalvular atrial fibrillation. Jpn Circ J 2000; 64:93-98.
37. Berger CE, Kröner A, Stiegler H, et al. Hypofibrinolysis, lipoprotein(a), and plasminogen activator inhibitor. Clin Orthopaed Related Res 2002; 397:342-349.
38. von Depka M, Newak-Göttl U, Eisert R, et al. Increased lipoprotein(a) levels as an independent risk factor for venous thromboembolism. Blood 2000; 96:3364-3368.
39. Newak-Göttl U, Junker R, Hartmeier M, et al. Increased lipoprotein(a) is an important risk factor for venous thromboembolism in childhood. Circulation 1999; 100:743-748.
40. Nowak-Göttl U, Sträter R, Heinecke A, et al. Lipoprotein(a) and genetic polymorphisms of clotting Factor V, prothrombin, and methylenetetrahydrofolate reductase are risk factors of spontaneous ischemic stroke in childhood. Blood 1999; 94:3678-3682.
41. Sträter R, Becket S, von Eckardstein A, et al. Prospective assessment of risk factors for recurrent stroke during childhood: a 5-year follow-up study. Lancet 2002; 360:1540-1545. A prospective study, in which children (aged 6 months to 18 years) diagnosed with arterial ischemic stroke were followed for an additional 20-56 months, was designed to identify risk factors for a second arterial ischemic stroke. Elevated Lp(a) and familial protein C deficiency were the only prothrombotic risk factors that were independent predictors of increased risk for second stroke. This report emphasizes the role that Lp(a) may play in thrombotic events not arising from atherosclerosis, since it is unlikely that any of the young patients examined in this study possessed significant atherosclerotic disease.
42. Nowak-Göttl U, Junker R, Kreuz W, et al. Risk of recurrent venous thrombosis in children with combined prothrombotic risk factors. Blood 2001; 97:858-862.
43. Dahl T, Kontny F, Slagsvold CE, et al. Lipoprotein(a), other lipoproteins and hemostatic profiles in patients with ischemic stroke: the relation to cardiogenic embolism. Cerebrovasc Dis 2000; 10:110-117.
44. Cerrato P, Imperiale D, Fornengo P, et al. Higher lipoprotein(a) levels in atherothrombotic than lacunar ischemic cerebrovascular disease. Neurology 2002; 58:653-655.
45. Lippi G, Bassi A, Brocco G, et al. Lipoprotein(a) concentration is not associated with venous thromboembolism in a case control study. Haematologica 1999; 84:726-729.
46. Libourel EJ, Bank I, Meinardi JR, et al. Co-segregation of thrombophilic disorders in factor V Leiden carriers; the contributions of factor VIII, factor XI, thrombin activatable fibrinolysis inhibitor and lipoprotein(a) to the absolute risk of venous thromboembolism. Haematologica 2002; 87:1068-1073.
47. Nowak-Göttl U, Kosch A, Schlegel N, et al. Thromboembolism in children. Curr Opin Hematol 2002; 9:448-453.